Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

cipargamin

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Highly enantioselective rhodium-catalyzed addition of arylboroxines to N-unprotected ketimines are realized for the first time by… Expand
2019
2019
The Plasmodium falciparum ATPase PfATP4 is the target of a diverse range of antimalarial compounds, including the clinical drug… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2018
2018
ABSTRACT For an increasing number of antimalarial agents identified in high-throughput phenotypic screens, there is evidence that… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2018
2018
The antimalarial activity of chemically diverse compounds, including the clinical candidate cipargamin, has been linked to the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
2016
2016
The spiroindolones, a new class of antimalarial medicines discovered in a cellular screen, are rendered less active by mutations… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2016
2016
ABSTRACT The MIC of an antimalarial drug for a particular infection is the drug level associated with a net parasite… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
2016
2016
KAE609 [(1′R,3′S)-5,7′-dichloro-6′-fluoro-3′-methyl-2′,3′,4′,9′-tetrahydrospiro[indoline-3,1′-pyridol[3,4-b]indol]-2-one] is a… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
2015
2015
ABSTRACT KAE609 represents a new class of potent, fast-acting, schizonticidal antimalarials. This study investigated the safety… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
2015
2015
I diseases remain a significant cause of morbidity and mortality, among which tuberculosis (TB) and malaria are among the biggest… Expand
Highly Cited
2014
Highly Cited
2014
ABSTRACT This first-in-human randomized, double-blind, placebo-controlled, ascending-single and -multiple oral dose study was… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3